AI Tools & Solutions for
Clinical Research

AI is transforming clinical research across the trial lifecycle: (1) patient identification — AI matches patients from EHR and real-world data to trial eligibility criteria, accelerating enrollment; (2) site selection — AI identifies the optimal trial sites based on patient population, investigator experience, and performance history; (3) protocol design — AI analyses historical trial data to optimise dosing, endpoints, and inclusion criteria; (4) adverse event detection — AI monitors safety data signals across trials in real time; (5) data management — AI extracts and reconciles data from multiple EDC and source systems; (6) regulatory submission preparation — AI drafts sections of clinical study reports and regulatory submissions. CROs like IQVIA and Parexel and pharma companies like Roche and Pfizer have deployed AI broadly.

Patient enrollment is the most common cause of trial delays (80% of trials fail to enroll on time). AI accelerates enrollment through: AI-powered patient identification from EHR data using natural language processing to extract clinical criteria not in structured fields; AI-powered site performance prediction identifying which sites will enroll fastest; real-world data (RWD) analysis to identify eligible patients outside trial sites; and AI patient-matching apps that alert potential participants about matching trials. Companies like Antidote, TriNetX, and Veeva Vault Clinical use AI to reduce enrollment timelines 30–50%, saving months of delay on trials where every week costs $500K–$1M+.

Clinical data management AI: extracts data from source documents (hospital records, lab reports, CRFs) using AI OCR and natural language processing; validates data against protocol requirements and flags inconsistencies automatically; performs risk-based monitoring by identifying sites with anomalous data patterns that warrant on-site investigation; and reconciles data across EDC, safety, and regulatory systems. AI data management tools (Medidata AI, Veeva Vault, and Oracle Health Sciences) reduce data management costs by 30–40% while improving data quality — critical for regulatory submission integrity.

AI pharmacovigilance tools: process millions of safety reports, literature references, and social media mentions for adverse event signals; aggregate and code adverse events from unstructured text automatically; perform disproportionality analysis to identify safety signals statistically; and generate PSUR and DSUR safety reports with AI-assisted drafting. The FDA and EMA both accept AI-assisted safety signal detection as part of pharmacovigilance programmes. Companies using AI pharmacovigilance report 60–70% reductions in manual case processing time and improved signal detection sensitivity.

Regulatory submission AI: aggregates and formats clinical trial data into submission-ready packages; drafts sections of clinical study reports (CSRs) from structured trial data; performs consistency checking across a submission package for contradictions or missing cross-references; and maintains version-controlled regulatory document management. While human expert review and authorship remain essential, AI assistance reduces submission preparation time by 30–40% and improves the consistency of large submission packages. Veeva Vault RIM and Liquent InSight are leading AI-enhanced regulatory information management platforms.

Clinical research AI ROI is among the highest in any industry due to the massive cost of drug development: 30–50% enrollment acceleration (at $500K–$1M per week of trial delay, this is worth hundreds of millions per approved drug); 30–40% data management cost reduction; 60–70% safety reporting time savings; and better regulatory submission quality reducing FDA Complete Response Letter risk. For a CRO managing 20 mid-size Phase II/III trials annually, AI enrollment optimisation alone can generate $50M–$200M in value for sponsor clients — a strong justification for significant AI investment.